Please login to the form below

Not currently logged in
Email:
Password:

Claes Buxfeldt joins NDA

He becomes its new HTA director

AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.

During the past 18 years, Buxfeldt’s career has seen him work on a variety of disease areas, supporting more than 30 molecules/brands in global positions.

He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

Dr Werner Van den Eynde, vice president for the NDA advisory board, said: “We are very happy to welcome Claes on board as our new HTA director.

“Claes’ expertise will allow us to provide an even better service to our clients.”

Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA area.

21st March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics